Yale University: Bipolar Disorder trials

The registry lists 14 Bipolar Disorder studies with Yale University as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsRecruitingNCT05786066Phase 2
• Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily RhythmsCompletedNCT05317481Not applicableResults posted
• Naltrexone for Antipsychotic-Induced Weight GainCompletedNCT01866098Not applicableResults posted
• Zonisamide for Heavy Drinkers With Bipolar DisorderTerminatedNCT01566370Phase 2Results posted
• Levetiracetam in the Management of Bipolar DepressionCompletedNCT00566150Not applicableResults posted
• Ceftriaxone in the Management of Bipolar DepressionTerminatedNCT00566111Not applicableResults posted
• Imaging mGluR5 and Synaptic Density in Psychiatric DisordersCompletedNCT03898297
• Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot TrialCompletedNCT03367533Phase 1
• Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar DisorderTerminatedNCT03206463Phase 1
• Examination of Glutamate and mGluR5 in Psychiatric DisordersCompletedNCT02727972
• Trial of Ketamine and Lithium Therapy in Bipolar DepressionWithdrawnNCT01768767Phase 2
• Benefits Management for People With Psychiatric DisabilitiesCompletedNCT01329393Phase 1
• Recovery Guide Intervention for Recurrent Psychiatric HospitalizationCompletedNCT00400166Not applicable
• Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional AntipsychoticsCompletedNCT00224276